| [1] |
Berger J. IgA glomerular deposits in renal disease [J]. Transplant Proc, 1969, 1(4): 939-944.
|
| [2] |
Lai KN, Tang SC, Schena FP, et al. IgA nephropathy [J]. Nat Rev Dis Primers, 2016, 2: 16001.
|
| [3] |
Le W, Liang S, Hu Y, et al. Long-term renal survival and related risk factors in patients with IgA nephropathy: results from a cohort of 1155 cases in a Chinese adult population [J]. Nephrol Dial Transplant, 2012, 27(4): 1479-1485.
|
| [4] |
Chen T, Li X, Li Y, et al. Prediction and risk stratification of kidney outcomes in IgA nephropathy [J]. Am J Kidney Dis, 2019, 74(3): 300-309.
|
| [5] |
He JW, Zhou XJ, Lv JC, et al. Perspectives on how mucosal immune responses, infections and gut microbiome shape IgA nephropathy and future therapies [J]. Theranostics, 2020, 10(25): 11462-11478.
|
| [6] |
曾彩虹. IgA肾病病理评估[J]. 中华医学杂志，2020, 100(30): 2332-2335.
|
| [7] |
Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 clinical practice guideline for the management of glomerular diseases [J]. Kidney Int, 2021, 100(4S): S1-S276.
|
| [8] |
Ai Z, Zhou Q, Huang F, et al. Long-term renal outcomes of IgA nephropathy presenting with different levels of proteinuria [J]. Clin Nephrol, 2020, 94(6): 290-296.
|
| [9] |
中国医师协会肾脏内科医师分会，中国中西医结合学会肾脏疾病专业委员会营养治疗指南专家协作组. 中国慢性肾脏病营养治疗临床实践指南(2021版)[J]. 中华医学杂志，2021, 101(8): 539-559.
|
| [10] |
中国中西医结合学会，中华中医药学会，中华医学会. IgA肾病中西医结合诊疗指南[EB/OL]. (2020-01-09)[2024-01-04].
URL
|
| [11] |
Hou FF, Zhang X, Zhang GH, et al. Efficacy and safety of benazepril for advanced chronic renal insufficiency [J]. N Engl J Med, 2006, 354(2): 131-140.
|
| [12] |
Lv J, Guo L, Wang R, et al. Efficacy and safety of sodium-glucose cotransporter-2 inhibitors in nondiabetic patients with chronic kidney disease: a review of recent evidence [J]. Kidney Dis (Basel), 2023, 9(5): 326-341.
|
| [13] |
Wheeler D, Toto R, Stefansson B, et al. A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy [J]. Kidney Int, 2021, 100(1): 215-224.
|
| [14] |
The EMPA-KIDNEY Collaborative Group; Herrington W, Staplin N, et al. Empagliflozin in patients with chronic kidney disease [J]. N Engl J Med, 2023, 388(2): 117-127.
|
| [15] |
Lv J, Zhang H, Wong MG, et al. Effect of oral methylprednisolone on clinical outcomes in patients with IgA nephropathy: the TESTING randomized clinical trial [J]. JAMA, 2017, 318(5): 432-442.
|
| [16] |
Lv J, Wong MG, Hladunewich MA, et al. Effect of oral methylprednisolone on gecline in kidney function or kidney failure in patients with IgA nephropathy: the TESTING randomized clinical trial [J]. JAMA, 2022, 327(19): 1888-1898.
|
| [17] |
Barratt J, Lafayette R, Kristensen J, et al. Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy [J]. Kidney Int, 2023, 103(2): 391-402.
|
| [18] |
Lafayette R, Kristensen J, Stone A, et al. Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial [J]. Lancet, 2023, 402(10405): 859-870.
|
| [19] |
Ballardie FW, Roberts ISD. Controlled prospective trial of prednisolone and cytotoxics in progressive IgA nephropathy [J]. J Am Soc Nephrol, 2002, 13(1): 142-148.
|
| [20] |
Liu L, Yang Y, Shi S, et al. Effects of hydroxychloroquine on proteinuria in IgA nephropathy: a randomized controlled trial [J]. Am J Kidney Dis, 2019, 74(1): 15-22.
|
| [21] |
Hou JH, Le WB, Chen N, et al. Mycophenolate mofetil combined with prednisone versus full-dose prednisone in IgA nephropathy with active proliferative lesions: a randomized controlled trial [J]. Am J Kidney Dis, 2017, 69(6): 788-795.
|
| [22] |
陈香美，陈仆，蔡广研，等. 麦考酚酸酯治疗IgA肾病的随访对照观察[J]. 中华医学杂志，2002, 82(12): 796-801.
|
| [23] |
Hou FF, Xie D, Wang J, et al. Effectiveness of mycophenolate mofetil among patients with progressive IgA nephropathy: a randomized clinical trial [J]. JAMA Netw Open, 2023, 6(2): e2254054.
|
| [24] |
徐明中，胡伟新，刘志红，等. 雷公藤多甙联合苯那普利和大黄素治疗IgA肾病的前瞻性临床研究[J]. 肾脏病与透析肾移植杂志，2004, 13(1): 19-24.
|
| [25] |
邱强，陈香美，吴杰，等. IgA肾病肾功能状态与病理分级的探讨[J]. 中华肾脏病杂志，2004, 20(z1): 6-10.
|
| [26] |
Tesar V, Troyanov S, Bellur S, et al. Corticosteroids in IgA nephropathy: a retrospective analysis from the VALIGA study [J]. J Am Soc Nephrol, 2015, 26(9): 2248-2258.
|
| [27] |
Du W, Chen Z, Fang Z, et al. Oral glucocorticoids with intravenous cyclophosphamide or oral glucocorticoids alone in the treatment of IgA nephropathy present with nephrotic syndrome and mesangioproliferative glomerulonephritis [J]. Clin Kidney J, 2023, 16(12): 2567-2577.
|
| [28] |
黎磊石，刘志红. 应用雷公藤治疗肾炎二十五载的体会[J]. 肾脏病与透析肾移植杂志，2003, 12(3): 246-247.
|
| [29] |
Wang Y, Zhao B, Dang X, et al. A novel SPE-LC-MRM strategy for serum demethylzeylasteral quantitation developed with an 18O-labeled internal standard [J]. Anal Bioanal Chem, 2024, 416(2): 467-474.
|
| [30] |
Li P, Lin H, Ni Z, et al. Efficacy and safety of Abelmoschus manihot for IgA nephropathy: a multicenter randomized clinical trial [J]. Phytomedicine, 2020, 76: 153231.
|
| [31] |
陈香美，陈以平，周柱亮，等. 肾乐胶囊治疗IgA肾病肺脾气虚证患者的前瞻性多中心随机对照临床研究[J]. 中国中西医结合杂志，2006, 26(12): 1061-1065.
|
| [32] |
陈香美，陈建，陈以平，等. 肾华片治疗IgA肾病(气阴两虚证)多中心随机对照临床观察[J]. 中国中西医结合杂志，2007, 27(2): 101-105.
|
| [33] |
Yang D, He L, Peng X, et al. The efficacy of tonsillectomy on clinical remission and relapse in patients with IgA nephropathy: a randomized controlled trial [J]. Ren Fail, 2016, 38(2): 242-248.
|
| [34] |
Chen Y, Tang Z, Wang Q, et al. Long-term efficacy of tonsillectomy in Chinese patients with IgA nephropathy [J]. Am J Nephrol, 2007, 27(2): 170-175.
|
| [35] |
上海市肾内科临床质量控制中心专家组. 慢性肾脏病早期筛查、诊断及防治指南(2022年版)[J]. 中华肾脏病杂志，2022, 38(5): 453-464.
|
| [36] |
中华医学会肾脏病学分会专家组. 中国慢性肾脏病患者血钾管理实践专家共识[J]. 中华肾脏病杂志，2020, 36(10): 781-792.
|
| [37] |
中国医师协会肾脏内科医师分会肾性贫血指南工作组. 中国肾性贫血诊治临床实践指南[J]. 中华医学杂志，2021, 101(20): 1463-1502.
|
| [38] |
Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease [J]. Kidney Int, 2022, 102(5S): S1-S127.
|
| [39] |
Agarwal R, Filippatos G, Pitt B, et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis [J]. Eur Heart J, 2022, 43(6): 474-484.
|
| [40] |
Fakhouri F, Schwotzer N, Cabiddu G, et al. Glomerular diseases in pregnancy: pragmatic recommendations for clinical management [J]. Kidney Int, 2023, 103(2): 264-281.
|
| [41] |
国家卫生健康委办公厅. 肾病专业医疗质量控制指标(2020年版)[EB/OL]. (2020-01-09)[2024-01-04].
URL
|